Key result
Single intravenous treatment with irbesartan-NP at the time of reperfusion significantly reduced infarct size and ameliorated left ventricular remodeling in a mouse model of myocardial ischemia-reperfusion injury.
Why the study?
Does nanoparticle-mediated delivery of irbesartan reduce infarct size and left ventricular remodeling in a mouse model of myocardial ischemia-reperfusion injury?
Does nanoparticle-mediated delivery of irbesartan reduce infarct size and left ventricular remodeling in a mouse model of myocardial ischemia-reperfusion injury?
Nanoparticle-mediated delivery of irbesartan offers a novel targeted approach to reduce ischemia-reperfusion injury and adverse remodeling following acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
Does not support clinical use; leaves open targeted irbesartan nanoparticle delivery for ischemia-reperfusion injury.
Myocardial ischemia-reperfusion (IR) injury limits the therapeutic effect of early reperfusion therapy for acute myocardial infarction (AMI), in which the recruitment of inflammatory monocytes plays a causative role. Here we develop bioabsorbable poly-lactic/glycolic acid (PLGA) nanoparticles incorporating irbesartan, an angiotensin II type 1 receptor blocker with a peroxisome proliferator-activated receptor (PPAR)γ agonistic effect (irbesartan-NP). In a mouse model of IR injury, intravenous PLGA nanoparticles distribute to the IR myocardium and monocytes in the blood and in the IR heart. Single intravenous treatment at the time of reperfusion with irbesartan-NP (3.0 mg kg(-1) irbesartan), but not with control nanoparticles or irbesartan solution (3.0 mg kg(-1)), inhibits the recruitment of inflammatory monocytes to the IR heart, and reduces the infarct size via PPARγ-dependent anti-inflammatory mechanisms, and ameliorates left ventricular remodeling 21 days after IR. Irbesartan-NP is a novel approach to treat myocardial IR injury in patients with AMI.
No takes yet. Share an insight, caveat, or question.
Nakano et al. (2016) studied Myocardial ischemia-reperfusion injury. Irbesartan-NP (PLGA nanoparticles incorporating irbesartan) vs. Saline, control nanoparticles, or irbesartan solution was evaluated on Infarct size 24 hours after reperfusion. Single intravenous treatment with irbesartan-NP at the time of reperfusion significantly reduced infarct size and ameliorated left ventricular remodeling in a mouse model of myocardial ischemia-reperfusion injury.
Synapse has enriched 10 related papers. Consider them for comparative context: